NeoGenomics, Inc. (NEO) Financial Ratios
26 years of historical data (2000–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
345.49
-2% vs avg
5yr avg: 351.84
30Y Low2.7·High95.0
P/FCF
N/A
—
5yr avg: N/A
30Y Low7.6·High181.5
P/B Ratio
↓
0.34
↓-23% vs avg
5yr avg: 0.44
30Y Low0.2·High144.0
ROE
↓
-12.4%
↑-39% vs avg
5yr avg: -8.9%
30Y Low-284%·High13%
Debt/EBITDA
270.65
+0% vs avg
5yr avg: 270.65
30Y Low1.1·High47.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NEO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NeoGenomics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $290M | $301M | $417M | $406M | $230M | $819M | $1.2B | $606M | $231M | $141M | $133M |
| Enterprise Value | $603M | $614M | $656M | $675M | $577M | $1.1B | $1.2B | $566M | $333M | $233M | $227M |
| P/E Ratio → | -2.65 | — | — | — | — | — | 283.37 | 75.00 | 90.07 | — | — |
| P/S Ratio | 0.40 | 0.41 | 0.63 | 0.69 | 0.45 | 1.69 | 2.71 | 1.48 | 0.83 | 0.59 | 0.54 |
| P/B Ratio | 0.34 | 0.36 | 0.46 | 0.43 | 0.23 | 0.74 | 1.73 | 1.19 | 0.72 | 0.68 | 0.71 |
| P/FCF | — | — | — | — | — | — | — | 181.48 | 7.58 | 32.38 | 9.53 |
| P/OCF | 55.49 | 57.61 | 59.44 | — | — | — | 824.52 | 25.94 | 5.16 | 7.80 | 6.19 |
P/E links to full P/E history page with 30-year chart
NEO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
NeoGenomics, Inc.'s enterprise value stands at 345.5x EBITDA, roughly in line with its 5-year average of 351.8x. The Healthcare sector median is 14.4x, placing the stock at a 2293% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | 0.99 | 1.14 | 1.13 | 2.30 | 2.68 | 1.38 | 1.20 | 0.97 | 0.93 |
| EV / EBITDA | 345.49 | 351.84 | — | — | — | — | 42.78 | 13.08 | 10.49 | 9.15 | 8.79 |
| EV / EBIT | — | — | — | — | — | — | — | 76.92 | 33.21 | 58.93 | 105.13 |
| EV / FCF | — | — | — | — | — | — | — | 169.46 | 10.94 | 53.68 | 16.25 |
NEO Profitability
Margins and return-on-capital ratios measuring operating efficiency
NeoGenomics, Inc. earns an operating margin of -9.1%. Operating margins have expanded from -18.2% to -9.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -12.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 38.8% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 45.2% |
| Operating Margin | -9.1% | -9.1% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% | 1.2% | 1.1% |
| Net Profit Margin | -14.9% | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 1.0% | -0.2% | -2.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.4% | -12.4% | -8.5% | -9.1% | -13.7% | -0.9% | 0.7% | 1.9% | 1.0% | -0.2% | -2.9% |
| ROA | -7.2% | -7.2% | -4.7% | -5.1% | -8.0% | -0.6% | 0.5% | 1.3% | 0.6% | -0.1% | -1.7% |
| ROIC | -4.3% | -4.3% | -5.9% | -6.3% | -8.6% | -8.5% | -1.8% | 2.2% | 2.1% | 0.8% | 0.7% |
| ROCE | -5.1% | -5.1% | -6.3% | -6.7% | -9.2% | -8.8% | -1.8% | 2.4% | 2.7% | 1.0% | 0.9% |
NEO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
NeoGenomics, Inc. carries a Debt/EBITDA ratio of 270.6x, which is highly leveraged (8318% above the sector average of 3.2x). Net debt stands at $313M ($472M total debt minus $160M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.56 | 0.56 | 0.67 | 0.65 | 0.61 | 0.55 | 0.31 | 0.26 | 0.35 | 0.51 | 0.57 |
| Debt / EBITDA | 270.65 | 270.65 | — | — | — | — | 7.82 | 3.07 | 3.53 | 4.14 | 4.12 |
| Net Debt / Equity | — | 0.37 | 0.26 | 0.29 | 0.35 | 0.27 | -0.02 | -0.08 | 0.32 | 0.45 | 0.50 |
| Net Debt / EBITDA | 179.17 | 179.17 | — | — | — | — | -0.38 | -0.93 | 3.23 | 3.63 | 3.63 |
| Debt / FCF | — | — | — | — | — | — | — | -12.02 | 3.36 | 21.30 | 6.72 |
| Interest Coverage | -17.61 | -17.61 | -11.19 | -13.06 | -20.02 | -14.45 | -1.00 | 1.98 | 1.61 | 0.71 | 0.22 |
NEO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NeoGenomics, Inc.'s current ratio of 4.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.94x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.20x to 4.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 4.26 | 1.98 | 6.20 | 6.73 | 7.81 | 6.13 | 4.55 | 1.70 | 2.42 | 1.32 |
| Quick Ratio | 3.94 | 3.94 | 1.89 | 5.95 | 6.46 | 7.54 | 5.73 | 4.32 | 1.56 | 2.21 | 1.21 |
| Cash Ratio | 1.81 | 1.81 | 1.28 | 4.31 | 4.87 | 5.91 | 4.05 | 2.71 | 0.16 | 0.37 | 0.21 |
| Asset Turnover | — | 0.53 | 0.40 | 0.35 | 0.29 | 0.26 | 0.45 | 0.58 | 0.55 | 0.70 | 0.72 |
| Inventory Turnover | 15.57 | 15.57 | 13.85 | 14.37 | 13.26 | 12.71 | 8.76 | 14.72 | 17.28 | 18.50 | 21.38 |
| Days Sales Outstanding | — | 79.91 | 83.18 | 80.98 | 85.72 | 84.50 | 87.74 | 85.03 | 101.45 | 91.80 | 83.01 |
NEO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NeoGenomics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.4% | 1.3% | 1.1% | — | — |
| FCF Yield | — | — | — | — | — | — | — | 0.6% | 13.2% | 3.1% | 10.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.7% | 0.0% | 41.4% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.7% | 0.0% | 41.4% |
| Shares Outstanding | — | $26M | $25M | $25M | $25M | $24M | $22M | $21M | $18M | $16M | $16M |
Peer Comparison
Compare NEO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NEOYou | $290M | -2.7 | 345.5 | — | 38.8% | -9.1% | -12.4% | -4.3% | 270.6 |
 SLNO | $3B | 135.9 | 158.9 | 59.1 | 98.6% | 7.9% | 6.0% | 3.8% | 0.2 |
 CDNA | $1B | -57.4 | — | 32.9 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $30B | -139.5 | — | 278.4 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 LH | $22B | 25.4 | 13.0 | 18.2 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
 DGX | $22B | 23.2 | 13.3 | 16.5 | 31.9% | 14.5% | 14.0% | 8.8% | 3.2 |
 MYRG | $7B | 59.2 | 30.1 | 29.9 | 11.5% | 4.4% | 18.8% | 18.3% | 0.5 |
 FLGT | $556M | -9.5 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 PGNY | $2B | 41.0 | 22.1 | 10.9 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 CGEN | $193M | 5.4 | 3.3 | 6.2 | 87.3% | 43.1% | 44.8% | 85.9% | 0.1 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 26 years · Updated daily
What if you invested $1,000 in NEO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in NEO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NEO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNEO vs SLNO — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Soleno Therapeutics, Inc..
Compare NowNEO — Frequently Asked Questions
Quick answers to the most common questions about buying NEO stock.
What is NeoGenomics, Inc.'s P/E ratio?
NeoGenomics, Inc.'s current P/E ratio is -2.7x. The historical average is 56.2x.
What is NeoGenomics, Inc.'s EV/EBITDA?
NeoGenomics, Inc.'s current EV/EBITDA is 345.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.4x.
What is NeoGenomics, Inc.'s ROE?
NeoGenomics, Inc.'s return on equity (ROE) is -12.4%. The historical average is -39.4%.
Is NEO stock overvalued?
Based on historical data, NeoGenomics, Inc. is trading at a P/E of -2.7x. Compare with industry peers and growth rates for a complete picture.
What are NeoGenomics, Inc.'s profit margins?
NeoGenomics, Inc. has 38.8% gross margin and -9.1% operating margin.
How much debt does NeoGenomics, Inc. have?
NeoGenomics, Inc.'s Debt/EBITDA ratio is 270.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.